

Freedom of Information Request: Our Reference CTMUHB_237_21

Thank you for your request for information received on the 8 June 2021, regarding new biologic medications. Please find the response from Cwm Taf Morgannwg University Health Board set out below:

You asked:

I am analysing the usage of new biologic medications for the treatment of dermatological and rheumatological conditions. I would greatly appreciate if you could answer the following two questions.

Q1. How many patients were treated in May 2021 (or latest available month) by the dermatology department with the following drugs:

- Baricitinib (Olmiant)
- Dupilumab (Dupixent)
- Ixekizumab (Taltz)
- Risankizumab (Skyrizi)
- Guselkumab (Tremfya)
- Secukinumab (Cosentyx)

Q2. How many patients were treated in May 2021 (or latest available month) by the rheumatology department with the following drugs:

- Baricitinib (Olmiant)
- Filgotinib (Jyseleca)
- Ixekizumab (Taltz)
- Secukinumab (Cosentyx)
- Upadacitinib (Rinvoq)

Our response:

Please find below as requested, tables populated with the data we hold for the period of May 2021.

Medicine - Dermatology	Number of Patients
Baricitinib (Olmiant)	0
Dupilumab (Dupixent)	13
Ixekizumab (Taltz)	0
Risankizumab (Skyrizi)	0
Guselkumab (Tremfya)	0
Secukinumab (Cosentyx)	0

Medicine - Rheumatology	Number of Patients
Baricitinib (Olmiant)	**
Filgotinib (Jyseleca)	0
Ixekizumab (Taltz)	**
Secukinumab (Cosentyx)	25
Upadacitinib (Rinvoq)	0

Please note the following:

1. Baricitinib: this medicine is provided by our Community Pharmacies and therefore the latest data available relates to March 2021.
2. Dermatology and Rheumatology: elements of these services are provided within the services of neighbouring Health Boards, Cardiff and Vale UHB and Swansea Bay UHB, hence the figures may appear to be low.
3. Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.